Dr. Helen Wu, the author of this paper previously did a strong paper on the same topic in July of '23 focusing on CCR 5. This paper is due in October and it seems a study follow-up on the same topic SHIV and CCR5 only this time she declares up front that she uses Leronlimab to support her conclusions/theory. We should keep a sharp eye out for Dr Helen Wu, PhD.